

Supplementary Material 1. Paradoxical activation of the MAPK signaling pathway in *BRAF* wild-type (*BRAF*^{WT}) cells following BRAF inhibitor monotherapy vs. encorafenib, cetuximab, and binimetinib triplet therapy in *BRAF* V600E-mutant tumors. (Created with BioRender.com.)

